ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1904

Mapping CTD-ILD in a Spanish Cohort – the NIRRVANA Registry
Abstract Number: 0956

Mapping Metabolic Changes in Skin Fibrosis in Systemic Sclerosis by Spatial Proteomics
Abstract Number: 2407

Mapping Neurological Involvement, Regional Disparities, and Moderators of the Central Nervous System in Adult-Onset Systemic Lupus Erythematosus: A Global Systematic Review and Meta-Analysis
Abstract Number: 1782

Mapping The Synovial Innervation Of The Human Knee Joint
Abstract Number: 0627

Marked Decline in SLE Mortality Despite Rising Mortality in the General Population During the COVID-19 Pandemic
Abstract Number: 1809

Mass Spectrometry-Based N-Terminomics Uncovers Proteolytic Signatures and Pathways in Juvenile Idiopathic Arthritis Synovial Fluid
Abstract Number: PP05

Mastering a Rare, Autoimmune Disease: My Journey Regaining Agency Through Education, Collaboration, and Community
Abstract Number: 2211

Maternal Adverse Pregnancy Outcomes and Risk Factors in Patients with Systemic Lupus Erythematosus in the United States
Abstract Number: 2203

Maternal and Fetal Outcomes Associated with IL-17 Inhibitor Exposure During Pregnancy in Patients with Seronegative Arthritis: A Case Series of Nine
Abstract Number: 0427

Maternal Smoking During Pregnancy and Risk of Juvenile Idiopathic Arthritis (JIA): Triangulating Evidence from Polygenic Risk Scores and Meta-Analysis in Scandinavian Birth Cohorts
Abstract Number: 2632

Maternal vascular malperfusion: association with adverse perinatal outcomes in lupus pregnancies
Abstract Number: 2457

Maternal, Embryo-Fetal And Neonatal Outcomes Following Belimumab Exposure During Pregnancy In Patients With Systemic Lupus Erythematosus
Abstract Number: 1801

Matrikine Activation of Synovial Fibroblasts Promotes Monocyte Migration and Stimulates an OA Chondrocyte Phenotype
Abstract Number: PP04

MCTD and Aging – Resilience Required
Abstract Number: 1216

Measurement Properties of a Shorter Health Assessment Questionnaire (HAQ-II) in Patients with Inflammatory Myopathies

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].